Natera, Inc. (45E.F)

86,00 0,00 (0,00%) Börsenschluss: 07:55PM CEST

Natera, Inc.

13011 McCallen Pass
Building A Suite 100
Austin, TX 78753
United States
650 980 9190
https://www.natera.com

Sektor(en): 
Branche: 
Vollzeitmitarbeiter: 3.282

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Matthew Rabinowitz Ph.D.	Co-Founder & Executive Chairman	713,32k	N/A	1973
Mr. Steven Leonard Chapman	CEO & Director	1,48M	N/A	1979
Mr. Michael B. Brophy M.B.A.	Chief Financial Officer	672,69k	N/A	1980
Mr. Daniel Rabinowitz L.L.M.	Secretary & Chief Legal Officer	566,85k	N/A	1969
Mr. John Fesko	President & Chief Business Officer	N/A	N/A	1979
Mr. Jonathan Sheena M.Eng.	Co-Founder & Director	272,85k	9,32M	1973
Ms. Olesya A. Anisimova CPA	Chief Accounting Officer	N/A	N/A	N/A
Mr. Rishi Kacker	Chief Technology Officer	N/A	N/A	N/A
Mr. Eric A. Evans	Chief Scientific Officer	N/A	N/A	N/A
Mr. Jerry Diffley	Chief Compliance & Privacy Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Corporate Governance

Natera, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 8. Die grundlegenden Scores sind Audit: 4, Vorstand: 8, Shareholderrechte: 8, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.